(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 January 2022 (13.01.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/010854 A1

(51) International Patent Classification:
A61K 9/16 (2006.01) *A61P 35/00* (2006.01)
A61K 9/48 (2006.01)

(21) International Application Number:
PCT/US2021/040452

(22) International Filing Date:
06 July 2021 (06.07.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/048,998 07 July 2020 (07.07.2020) US

(71) Applicant: **CELGENE CORPORATION** [US/US]; 86 Morris Avenue, Summit, NJ 07901 (US).

(72) Inventors: **AGRAWAL, Anjali**; Celgene Summit West, 556 Morris Avenue, Summit, NJ 07901 (US). **MITRA, Biplob, K.**; Celgene Summit West, 556 Morris Avenue, Summit, NJ 07901 (US). **THOOL, Prajwal, Gunwanth**; Celgene Summit West, 556 Morris Avenue, Summit, NJ 07901 (US). **HIGGINS-GRUBER, Shannon**; Celgene Summit West, 556 Morris Avenue, Summit, NJ 07901 (US). **RODRIGUEZ, Jennifer, Almodovar**; Celgene Summit West, 556 Morris Avenue, Summit, NJ 07901 (US). **LIU, Demin**; Celgene Summit West, 556 Morris Avenue, Summit, NJ 07901 (US).

(74) Agent: **BRUNER, Michael, J.** et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)M ETHYL) BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE AND METHODS OF USING THE SAME




FIG. 1A




FIG. 1B

(57) Abstract: Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4- yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent. Also provided herein are methods of preparing and methods of using the pharmaceutical compositions.

[Continued on next page]

WO 2022/010854 A1

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*